Product menu

Postherpetic neuralgia (PHN) data and efficacy data at four years in adults ≥50 years (ZOE-50 and ZOE-70)

By helping prevent shingles, SHINGRIX significantly decreased the incidence of PHN in patients aged ≥70 overall1*

Table with efficacy data for postherpetic neuralgia from the ZOE-50 and ZOE-70 clinical trials Table with efficacy data for postherpetic neuralgia from the ZOE-50 and ZOE-70 clinical trials

Adapted from SHINGRIX Product Monograph.

8,250 PATIENTS ≥70 YEARS OF AGE RECEIVED SHINGRIX.1

FOUR CASES OF PHN WERE REPORTED IN THIS AGE GROUP.1

The benefit of SHINGRIX on PHN can be attributed to the effect of the vaccine on the prevention of HZ. A further reduction of PHN incidence in subjects with confirmed HZ could not be demonstrated due to the limited number of HZ cases in the vaccine group.¹

SHINGRIX is not indicated for the treatment of HZ or PHN.1

* PHN was defined as shingles-associated pain rated as ≥3 on a 0–10 scale, occurring or persisting for at least 90 days following the onset of rash using the Zoster Brief Pain Inventory questionnaire.1,2

Efficacy remained high four years post-vaccination in adults ≥70 years old1,2

Efficacy 4 years post-vaccination (ZOE-50 and ZOE-70 pooled data) graph Efficacy 4 years post-vaccination (ZOE-50 and ZOE-70 pooled data) graph

Based on pooled data from ZOE-50 and ZOE-70.

Efficacy remained high four years post-vaccination in adults ≥50 years old1

Cumulative incidence of herpes zoster over time in adults aged ≥50 in the ZOE-50 study (mTVC)1

In the fourth year after vaccination, vaccine efficacy (VE) against shingles in patients ≥50 years in ZOE-50 was 93.1% vs. placebo (95% CI: 81.2, 98.2).1

Efficacy 4 years post-vaccination (ZOE-50 data) graph Efficacy 4 years post-vaccination (ZOE-50 data) graph

Adapted from SHINGRIX Product Monograph.

Efficacy remained high four years post-vaccination in adults ≥70 years old1

Cumulative incidence of herpes zoster over time in adults aged ≥70 in the pre-specified pooled ZOE-50/ZOE-70 analysis (mTVC)1

In the fourth year after vaccination, VE against shingles in patients ≥70 years was 87.9% vs. placebo (95% CI: 73.3, 95.4).1

Efficacy 4 years post-vaccination (pre-specified pooled ZOE-50/ZOE-70 analysis) graph Efficacy 4 years post-vaccination (pre-specified pooled ZOE-50/ZOE-70 analysis) graph

Adapted from SHINGRIX Product Monograph.

Patient icon

Meet the patients that are eligible to receive SHINGRIX

Nearly everyone ≥50 years old should be protected against shingles.3

Learn more
Virus icon

What was shown to be the dominant driver of shingles?

Learn about age-related decline in immunity.4

Learn more
cross icon

The safety profile of SHINGRIX in adults ≥50 years was extensively studied in two large phase III clinical trials (ZOE-50 and ZOE-70)1-3

Learn more about the safety profile of SHINGRIX.1

Learn more

References:

  1. SHINGRIX Product Monograph. GlaxoSmithKline Inc., November 15, 2022.
  2. Cunningham AL et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med 2016;375(11):1019-1032.
  3. Public Health Agency of Canada. An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI) – Updated Recommendations on the Use of Herpes Zoster Vaccines. Ottawa, Ontario: Public Health Agency of Canada; June 2018. Available at: https://www.canada.ca/en/services/health/publications/healthy-living/updated-recommendations-use-herpes-zoster-vaccines.html. Accessed November 30, 2022.
  4. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008;57(RR-5):1-30.

Trademarks are owned by or licensed to the GSK group of companies.

©2022 GSK Group of Companies or its licensor.

10661 | 06/23